2020 BD launched the first Human Papillomavirus (HPV) test with extended genotyping to detect more types of HPV, the dominant cause of cervical cancer.
2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process.
2020 BD launched the BD Veritor™ Plus System for rapid detection of COVID-19
2021 BD launched the first atherectomy and thrombectomy device in the U.S. indicated to treat in-stent restenosis.
2021 BD launched the first at-home system in the U.S. indicated for malignant and non-malignant ascites drainage.
2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution.
2021 BD launched the first assay for HPV screening from at-home, self-collected vaginal samples.
2021 BD launched the first smartphone-interpreted rapid at-home COVID-19 test.
2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second).
2022 BD celebrates their 125th anniversary by ringing the closing bell at the New York Stock Exchange.